aTyr Pharma (NASDAQ:ATYR) Issues Quarterly Earnings Results

aTyr Pharma (NASDAQ:ATYR) issued its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04, FiscalAI reports.

aTyr Pharma Stock Down 6.4%

NASDAQ:ATYR traded down $0.06 during trading hours on Thursday, hitting $0.90. 1,293,234 shares of the company traded hands, compared to its average volume of 2,013,049. The company has a market cap of $88.42 million, a PE ratio of -1.09 and a beta of 0.55. The firm’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.47. aTyr Pharma has a one year low of $0.64 and a one year high of $7.29.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $25.67.

Institutional Trading of aTyr Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of aTyr Pharma by 21.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after purchasing an additional 975,887 shares during the period. UBS Group AG increased its holdings in aTyr Pharma by 158.1% during the third quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock worth $3,249,000 after buying an additional 2,760,238 shares during the last quarter. Octagon Capital Advisors LP increased its holdings in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock worth $19,367,000 after buying an additional 268,000 shares during the last quarter. Geode Capital Management LLC raised its position in aTyr Pharma by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock worth $1,789,000 after acquiring an additional 105,514 shares during the period. Finally, Millennium Management LLC increased its stake in shares of aTyr Pharma by 22.0% during the 3rd quarter. Millennium Management LLC now owns 1,890,921 shares of the company’s stock worth $1,364,000 after purchasing an additional 340,721 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.